Pomegra
JPMorgan, a16z and Carlyle co-lead the hypersonic missile maker's round, more than tripling its valuation from a $350 million Series B just 13 months earlier.
Key Takeaways
- Castelion raised $800 million in equity plus a $250 million revolving credit facility, for over $1 billion total.
- The round values the Torrance, California defense-tech startup at $13 billion.
- Proceeds fund mass production of the Blackbeard hypersonic missile, targeted to field in 2027.
Lead
Castelion, a defense-tech startup building low-cost hypersonic weapons, closed a Series C financing of more than $1 billion on August 19, 2026, comprising $800 million in equity and a $250 million committed revolving credit facility. The round was co-led by JPMorganChase's Strategic Investment Group, Andreessen Horowitz and funds managed by Carlyle, and values the company at $13 billion. It arrives roughly 13 months after Castelion's $350 million Series B, a jump that reflects both the Pentagon's urgency to close a hypersonic gap with China and Russia and investors' growing appetite for defense manufacturing bets.
What Does Castelion Actually Build?
Castelion designs and manufactures Blackbeard, a hypersonic strike missile the company describes as the first U.S. system engineered from the outset for industrial-scale output and commercial-grade unit costs rather than bespoke, low-volume production. Founded by SpaceX alumni Bryon Hargis, Sean Pitt and Andrew Kreitz, the company took Blackbeard from a clean-sheet design to a Pentagon program of record in under four years - fast by the standards of a weapons category historically defined by decade-long, cost-overrun-prone development cycles. Castelion has booked more than $500 million in U.S. military contracts over the past 18 months, and Blackbeard fielding is targeted for 2027.
Who Else Put Money In?
Beyond the three co-leads, the round drew participation from Lightspeed Venture Partners, Lavrock Ventures, Altimeter, General Catalyst and Interlagos - all repeat backers from the Series B - plus new investor T. Rowe Price Associates. The mutual-fund manager's entry is notable: T. Rowe typically invests in late-stage private companies it expects to eventually take public, a signal that Castelion is being underwritten as a pre-IPO asset rather than a pure venture play.
Why Did the Valuation Triple in a Year?
Castelion's valuation jumped from an undisclosed Series B mark to $13 billion, more than tripling the $350 million it raised in mid-2025, on the strength of executed contracts rather than projected ones. Half a billion dollars in military awards over 18 months gives investors revenue evidence that most defense startups can't show at this stage, and it lets the round be priced against near-term Pentagon procurement rather than speculative demand. The credit facility structure - $250 million of the total is debt, not equity - also signals lenders' confidence that Blackbeard production will generate predictable cash flow once manufacturing scales, a bet closer to industrial finance than venture underwriting.
Strategic Context
The raise lands inside a broader defense-tech funding wave that has pulled in Anduril, Saronic and other venture-backed hardware makers competing for Pentagon dollars traditionally reserved for Lockheed Martin, RTX and Northrop Grumman. Hypersonic weapons - missiles that travel above Mach 5 and maneuver to evade existing missile defenses - sit near the top of the Pentagon's modernization list after years of concern that China and Russia have fielded operational systems faster than the U.S. Castelion's pitch is explicitly cost-driven: building Blackbeard on commercial manufacturing lines rather than the artisanal, low-rate production that has kept legacy hypersonic programs expensive and slow.
What Comes Next for Castelion?
The new capital is earmarked for expanded manufacturing capacity, primarily in New Mexico, alongside development of a longer-range strike weapon and new air and missile defense systems beyond Blackbeard. Fielding Blackbeard by 2027 remains the near-term milestone investors will watch, since a defense startup's valuation is only as durable as its ability to convert contracts into delivered hardware. A miss on that timeline would test whether a $13 billion mark can hold without recurring production revenue behind it.
Outlook
Castelion's Series C confirms that private capital is willing to underwrite hypersonic weapons manufacturing at a scale once reserved for primes with decades of government contracting history. The presence of a mutual-fund investor and a sizable credit facility points toward an eventual public listing, though that remains speculative. The real test is operational: whether Blackbeard reaches the field in 2027 at the low unit cost Castelion has promised, or whether the company runs into the same cost and schedule pressures that have plagued hypersonic programs for decades.
